365 related articles for article (PubMed ID: 10593346)
1. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
Hensrud DD; Connolly HM; Grogan M; Miller FA; Bailey KR; Jensen MD
Mayo Clin Proc; 1999 Dec; 74(12):1191-7. PubMed ID: 10593346
[TBL] [Abstract][Full Text] [Related]
2. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL
JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496
[TBL] [Abstract][Full Text] [Related]
3. The longitudinal effects of fenfluramine-phentermine use.
Fleming RM; Boyd LB
Angiology; 2007; 58(3):353-9. PubMed ID: 17626991
[TBL] [Abstract][Full Text] [Related]
4. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.
Gardin JM; Weissman NJ; Leung C; Panza JA; Fernicola D; Davis KD; Constantine GD; Reid CL
JAMA; 2001 Oct 24-31; 286(16):2011-4. PubMed ID: 11667938
[TBL] [Abstract][Full Text] [Related]
5. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months.
Burger AJ; Sherman HB; Charlamb MJ; Kim J; Asinas LA; Flickner SR; Blackburn GL
J Am Coll Cardiol; 1999 Oct; 34(4):1153-8. PubMed ID: 10520805
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT
N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086
[TBL] [Abstract][Full Text] [Related]
7. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
[TBL] [Abstract][Full Text] [Related]
8. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
Ryan DH; Bray GA; Helmcke F; Sander G; Volaufova J; Greenway F; Subramaniam P; Glancy DL
Obes Res; 1999 Jul; 7(4):313-22. PubMed ID: 10440587
[TBL] [Abstract][Full Text] [Related]
9. Valvular heart disease associated with fenfluramine-phentermine.
Connolly HM; Crary JL; McGoon MD; Hensrud DD; Edwards BS; Edwards WD; Schaff HV
N Engl J Med; 1997 Aug; 337(9):581-8. PubMed ID: 9271479
[TBL] [Abstract][Full Text] [Related]
10. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs.
Burger AJ; Charlamb MJ; Singh S; Notarianni M; Blackburn GL; Sherman HB
Int J Cardiol; 2001 Jul; 79(2-3):159-65. PubMed ID: 11461737
[TBL] [Abstract][Full Text] [Related]
11. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.
Teramae CY; Connolly HM; Grogan M; Miller FA
Mayo Clin Proc; 2000 May; 75(5):456-61. PubMed ID: 10807073
[TBL] [Abstract][Full Text] [Related]
12. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
N Engl J Med; 1998 Sep; 339(11):725-32. PubMed ID: 9731088
[TBL] [Abstract][Full Text] [Related]
13. Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.
Whigham LD; Dhurandhar NV; Rahko PS; Atkinson RL
Int J Obes (Lond); 2007 May; 31(5):850-7. PubMed ID: 17146452
[TBL] [Abstract][Full Text] [Related]
14. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.
Wee CC; Phillips RS; Aurigemma G; Erban S; Kriegel G; Riley M; Douglas PS
Ann Intern Med; 1998 Dec; 129(11 Pt 1):870-4. PubMed ID: 9867728
[TBL] [Abstract][Full Text] [Related]
15. Valvular heart disease in fenfluramine- phentermine-treated patients: a comparison with control patients.
Wadden TA; Silvestry FE; Aber JL; Berkowitz RI; Foster GD; Sutton MG
Obes Res; 1999 May; 7(3):309-10. PubMed ID: 10348504
[No Abstract] [Full Text] [Related]
16. Operation for anorexigen-associated valvular heart disease.
Caccitolo JA; Connolly HM; Rubenson DS; Orszulak TA; Schaff HV
J Thorac Cardiovasc Surg; 2001 Oct; 122(4):656-64. PubMed ID: 11581595
[TBL] [Abstract][Full Text] [Related]
17. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.
Kancherla MK; Salti HI; Mulderink TA; Parker M; Bonow RO; Mehlman DJ
Am J Cardiol; 1999 Dec; 84(11):1335-8. PubMed ID: 10614800
[TBL] [Abstract][Full Text] [Related]
18. Dose effect of fenfluramine-phentermine in the production of valvular heart disease.
Tovar EA; Landa DW; Borsari BE
Ann Thorac Surg; 1999 Apr; 67(4):1213-4. PubMed ID: 10320298
[No Abstract] [Full Text] [Related]
19. Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study.
Palmieri V; Arnett DK; Roman MJ; Liu JE; Bella JN; Oberman A; Kitzman DW; Hopkins PN; Morgan D; de Simone G; Devereux RB
Am J Med; 2002 Jun; 112(9):710-5. PubMed ID: 12079711
[TBL] [Abstract][Full Text] [Related]
20. Valvular heart disease with the use of fenfluramine-phentermine.
Surapaneni P; Vinales KL; Najib MQ; Chaliki HP
Tex Heart Inst J; 2011; 38(5):581-3. PubMed ID: 22163141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]